Replies to post #185660 on Biotech Values

[kris_kade]

CYNAF (Cynapsus Pharma, a Canadian co) is IMO, a better value in treatment of Parkinson's on/off episodes. Their MOA is sublingual vs inhaling that Civitas (private co) has which recently acquired by ACOR at substantial premium.

Cynapsus recently published impressive trial results that clearly showed safety and efficacy. They have scheduled meetings with FDA next month for discussions on P3 trial design

Disclaimer: Long on CYNAF

[WID]

AMPYRA is currently protected by five patents listed in the FDA’s Approved Drugs Product List (Orange Book), four of which extend into 2025, 2026 and 2027, respectively. AMPYRA also has Orphan Drug status, which extends into January 2017.

Actavis is the one who files an ANDA for generic AMPYRA.

[DewDiligence]

ACOR +30%/AH on USPTO denial of the inter partes review requested by Kyle Bass:

http://finance.yahoo.com/news/acorda-announces-patent-trials-appeal-214200015.html